Advertisement

Guidelines, Consensus Conferences and Overviews (Meta-analysis)

  • Kathleen I. Pritchard
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 151)

In the practice of oncology, and even in sub-specialties such as the care of women with breast cancer, it can be challenging and sometimes overwhelming to keep up to date with the latest discoveries and publications. In the past few years, the review article [1, 2] was the standard vehicle for keeping up to date for most clinicians. Review articles of this type, while often excellent summations of the available data, did not use explicit criteria for the inclusion or weighting of evidence from articles which often had wide variability in methodologic quality. Furthermore, today’s methods of rapid computer-based formalized literature retrieval were not available at that time. In spite of that limitation, however, published articles were usually accessible using hand searching methods which are still an important part of all literature reviews and guideline productions [3–5]. More problematic in such reviews was the lack of access to unpublished material, since review articles and indeed even consensus documents, guidelines and meta-analyses of published data do not usually attempt to retrieve such data.

Keywords

National Comprehensive Cancer Network National Comprehensive Cancer Network Contralateral Breast Cancer Consensus Meeting Ovarian Ablation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Henderson IC, Canellos GP. Cancer of the breast: The past decade (first of two parts). N Engl J Med. 1980;302:17–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Henderson IC, Canellos GP. Cancer of the breast: The past decade (second of two parts). N Engl J Med. 1980;302:78–90.PubMedCrossRefGoogle Scholar
  3. 3.
    Browman GP, Levine MN, Mohide EA, et al. The practice guidelines development cycle: A conceptual tool for practice guidelines development and implementation. J Clin Oncol. 1995;13:502–12.PubMedGoogle Scholar
  4. 4.
    Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women. N Engl J Med. 1988;319:1681–92.CrossRefGoogle Scholar
  5. 5.
    Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–717.CrossRefGoogle Scholar
  6. 6.
    De Angelis C, Drazen JM, Frizelle F, et al. Clinical trial registration: A statement from the International Committee of Medical Journal Editors. Ann Intern Med. 2004;141:477–8.PubMedGoogle Scholar
  7. 7.
    Tam VC, Hotte SJ. Consistency of phase III clinical trials abstracts presented at an annual meeting of the American Society of Clinical Oncology compared with their subsequent full-text publications. J Clin Oncol. 2008;26:2205–11.PubMedCrossRefGoogle Scholar
  8. 8.
    Chalmers TC, Matta R.J., Smith H Jr, Kunzler AM. Evidence favouring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Eng J Med. 1977;297:1097.CrossRefGoogle Scholar
  9. 9.
    Rosenthal R. Combining results of independent studies. Psych Bulletin. 1978;85:185–93.CrossRefGoogle Scholar
  10. 10.
    Goldman L, Feinstein AR. Angicoagulants and myocardial infarction: The problems of pooling, drowning and floating. Ann Inter Med. 1979;90:92–4.Google Scholar
  11. 11.
    Delozier T, Juret P, Couette JE, Mace-Lesech J. Ovarian irradiation in postmenopausal women with breast cancer and positive axillary nodes. In: Early Breast Cancer Trialists' Collaborative Group, ed. Treatment of Early Breast Cancer. Worldwide Evidence 1985–1990. A Systematic Overview of all Available Randomized Trials of Adjuvant Endocrine and Cytoxic Therapy. Oxford: Oxford University Press; 1990:114.Google Scholar
  12. 12.
    Pritchard KI. Ovarian ablation as adjuvant therapy for premenopausal women with early breast cancer: Phoenix arisen? (Editorial). Lancet. 1992;339:95–6.CrossRefGoogle Scholar
  13. 13.
    Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: An overview of the randomized trials. Lancet. 1996;348:1189–96.CrossRefGoogle Scholar
  14. 14.
    Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet. 1998;351:1451–67.CrossRefGoogle Scholar
  15. 15.
    Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet. 1998;352:930–42.CrossRefGoogle Scholar
  16. 16.
    Personal communication with Sir Richard Peto. 2008.Google Scholar
  17. 17.
    Ingle JN, Dowsett AG, Cuzick J, Davies C, Early Breast Cancer Trialists' Collaborative Group. Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: Meta-analysis of randomized trials of monotherapy and switching strategies. Br Cancer Res Treat. 2008;106. Abstract 107.Google Scholar
  18. 18.
    Peto R, Davies C. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women preliminary results [abstract]. Br Cancer Res Treat. 2007;106.Abstract 48.Google Scholar
  19. 19.
    Earl H, Gray R, Kerr D, Lee M. The optimal duration of adjuvant tamoxifen treatment for breast cancer remains uncertain: Randomize into ATom. Clin Oncol (R Coll Radiol). 1997;9:141–43.CrossRefGoogle Scholar
  20. 20.
    Abrams JS, Eifel P. Monograph Overview. Monogr Natl Cancer Inst. 2001;30:1–4.CrossRefGoogle Scholar
  21. 21.
    Office the Director NIH. Guidelines for the planning and management of NIH Consensus Development Conferences. NIH. 1993. Report http://consensus.nih.gov
  22. 22.
    Moxley JH, Allegra JC, Henney J, Muggia FM. Treatment of primary breast cancer: Summary of the National Institutes of Health Consensus Development Conference. JAMA. 1980;244:797–803.PubMedCrossRefGoogle Scholar
  23. 23.
    Consensus Conference. Adjuvant chemotherapy for breast cancer. JAMA. 1985; 254:3461–3.CrossRefGoogle Scholar
  24. 24.
    NIH Consensus Conference. Treatment of early stage breast cancer. JAMA. 1991;265:391–5.CrossRefGoogle Scholar
  25. 25.
    National Institutes of Health Consensus Development Panel. The National Institutes of Health Consensus Development Conference: Adjuvant therapy for breast cancer. J Natl Cancer Inst. 2001;30:1–152.Google Scholar
  26. 26.
    National Institutes of Health Consensus Panel. National Institiutes of Health Consensus Development Conference statement: Adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst. 2001;93:979–89.CrossRefGoogle Scholar
  27. 27.
    Bryant J., Fisher B, Dignam J. Duration of Adjuvant Tamoxifen Therapy. J Natl Cancer Inst. 2001;30:56–61.Google Scholar
  28. 28.
    Davidson N.E. Ovarian ablation as adjuvant therapy for breast cancer. J Natl Cancer Inst. 2001;30:67–71.Google Scholar
  29. 29.
    Balaban EP, Brouwers M, Temin SB, Lyman GH. Issues in clinical practice guideline implementation and utilization. ASCO Educational Book. In press 2009.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Kathleen I. Pritchard
    • 1
  1. 1.Sunnybrook Research Institute Medical Oncologist, Sunnybrook Odette Cancer Centre, Professor, Department of Medicine, Faculty of Medicine, University of TorontoTorontoCanada

Personalised recommendations